当前位置: 首页 >> 检索结果
共有 3431 条符合本次的查询结果, 用时 2.5768971 秒

541. Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.

作者: Xinrong Zhang.;Terry Cheuk-Fung Yip.;Grace Lai-Hung Wong.;Wei-Xuan Leow.;Lilian Yan Liang.;Lee-Ling Lim.;Guanlin Li.;Luqman Ibrahim.;Huapeng Lin.;Jimmy Che To Lai.;Angel Mei-Ling Chim.;Henry Lik Yuen Chan.;Alice Pik-Shan Kong.;Wah Kheong Chan.;Vincent Wai-Sun Wong.
来源: Gut. 2023年72卷12期2364-2371页
We aimed to test the hypothesis that automated fibrosis score calculation and electronic reminder messages could increase the detection of advanced liver disease in patients with type 2 diabetes.

542. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma.

作者: Xiaomeng Liu.;Rong Tang.;Jin Xu.;Zhen Tan.;Chen Liang.;Qingcai Meng.;Yubin Lei.;Jie Hua.;Yiyin Zhang.;Jiang Liu.;Bo Zhang.;Wei Wang.;Xianjun Yu.;Si Shi.
来源: Gut. 2023年72卷12期2329-2343页
Pancreatic ductal adenocarcinoma (PDAC) is among the most immunosuppressive tumour types. The tumour immune microenvironment (TIME) is largely driven by interactions between immune cells and heterogeneous tumour cells. Here, we aimed to investigate the mechanism of tumour cells in TIME formation and provide potential combination treatment strategies for PDAC patients based on genotypic heterogeneity.

543. Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8+ T cells.

作者: Frances Winkler.;Anna V Hipp.;Carlos Ramirez.;Bianca Martin.;Matteo Villa.;Emilia Neuwirt.;Oliver Gorka.;Jeroen Aerssens.;Susanne E Johansson.;Nisha Rana.;Sian Llewellyn-Lacey.;David A Price.;Marcus Panning.;Olaf Groß.;Erika L Pearce.;Carl M Hermann.;Kathrin Schumann.;Luciana Hannibal.;Christoph Neumann-Haefelin.;Tobias Boettler.;Percy Knolle.;Maike Hofmann.;Dirk Wohlleber.;Robert Thimme.;Bertram Bengsch.
来源: Gut. 2023年72卷10期1971-1984页
Exhausted T cells with limited effector function are enriched in chronic hepatitis B and C virus (HBV and HCV) infection. Metabolic regulation contributes to exhaustion, but it remains unclear how metabolism relates to different exhaustion states, is impacted by antiviral therapy, and if metabolic checkpoints regulate dysfunction.

544. IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells.

作者: Karen Anne-Marie Ullrich.;Julia Derdau.;Carsten Baltes.;Alice Battistella.;Gonzalo Rosso.;Stefan Uderhardt.;Lisa Lou Schulze.;Li-Juan Liu.;Mark Dedden.;Marta Spocinska.;Lucina Kainka.;Markéta Kubánková.;Tanja Martina Müller.;Nina-Maria Schmidt.;Emily Becker.;Oumaima Ben Brahim.;Imke Atreya.;Susetta Finotto.;Iryna Prots.;Stefan Wirtz.;Benno Weigmann.;Rocío López-Posadas.;Raja Atreya.;Arif Bülent Ekici.;Franziska Lautenschläger.;Jochen Guck.;Markus F Neurath.;Sebastian Zundler.
来源: Gut. 2023年72卷11期2081-2094页
IL-3 has been reported to be involved in various inflammatory disorders, but its role in inflammatory bowel disease (IBD) has not been addressed so far. Here, we determined IL-3 expression in samples from patients with IBD and studied the impact of Il3 or Il3r deficiency on T cell-dependent experimental colitis. We explored the mechanical, cytoskeletal and migratory properties of Il3r-/- and Il3r+/+ T cells using real-time deformability cytometry, atomic force microscopy, scanning electron microscopy, fluorescence recovery after photobleaching and in vitro and in vivo cell trafficking assays. We observed that, in patients with IBD, the levels of IL-3 in the inflamed mucosa were increased. In vivo, experimental chronic colitis on T cell transfer was exacerbated in the absence of Il-3 or Il-3r signalling. This was attributable to Il-3r signalling-induced changes in kinase phosphorylation and actin cytoskeleton structure, resulting in increased mechanical deformability and enhanced egress of Tregs from the inflamed colon mucosa. Similarly, IL-3 controlled mechanobiology in human Tregs and was associated with increased mucosal Treg abundance in patients with IBD. Collectively, our data reveal that IL-3 signaling exerts an important regulatory role at the interface of biophysical and migratory T cell features in intestinal inflammation and suggest that this might be an interesting target for future intervention.

545. Patient-reported experience of colonoscopy in Italy: a multicentre prospective observational study.

作者: Lorenzo Fuccio.;Colin J Rees.;Leonardo Frazzoni.;Laura Neilson.;Franco Radaelli.;Linda Sharp.;Cesare Hassan.;Cristiano Spada.; .
来源: Gut. 2023年72卷12期2227-2230页

546. Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies: a microsimulation and threshold analyses.

作者: Monica Saumoy.;Devika Gandhi.;Seth Buller.;Shae Patel.;Yecheskel Schneider.;Gregory Cote.;Michael L Kochman.;Nikhil R Thiruvengadam.;Reem Z Sharaiha.
来源: Gut. 2023年72卷12期2250-2259页
Weight loss interventions to treat obesity include sleeve gastrectomy (SG), lifestyle intervention (LI), endoscopic sleeve gastroplasty (ESG) and semaglutide. We aimed to identify which treatments are cost-effective and identify requirements for semaglutide to be cost-effective.

547. Tailoring treatment to the circumstance: reasoning behind metal versus plastic drainage of pancreatic collections.

作者: Giuseppe Vanella.;Michiel Bronswijk.;Schalk Willem Van der Merwe.;Paolo Giorgio Arcidiacono.
来源: Gut. 2024年73卷8期1391页

548. TIPSS plus extrahepatic collateral embolisation may decrease variceal rebleeding and post-TIPSS hepatic encephalopathy.

作者: Lianhui Zhao.;Qiong Wu.;Qian Li.;Anbang Chen.;Yifu Xia.;Xiubin Sun.;Jidong Jia.;Shan Shan.;Guangchuan Wang.;Chunqing Zhang.
来源: Gut. 2024年73卷7期1224-1226页

549. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity.

作者: Yongsheng Li.;Zhiyong Shen.;Zhen Chai.;Yizhi Zhan.;Yaowei Zhang.;Zhengyu Liu.;Yuechen Liu.;Zhenkang Li.;Mingdao Lin.;Zhanqiao Zhang.;Wei Liu.;Shenyuan Guan.;Jinchao Zhang.;Junying Qian.;Yi Ding.;Guoxin Li.;Yuan Fang.;Haijun Deng.
来源: Gut. 2023年72卷12期2307-2320页
Checkpoint immunotherapy unleashes T-cell control of tumours but is suppressed by immunosuppressive myeloid cells. The transmembrane protein MS4A4A is selectively highly expressed in tumour-associated macrophages (TAMs). Here, we aimed to reveal the role of MS4A4A+ TAMs in regulating the immune escape of tumour cells and to develop novel therapeutic strategies targeting TAMs to enhance the efficacy of immune checkpoint inhibitor (ICI) in colorectal cancer.

550. Growth rates and histopathological outcomes of small (6-9 mm) colorectal polyps based on CT colonography surveillance and endoscopic removal.

作者: B Dustin Pooler.;David H Kim.;Kristina A Matkowskyj.;Michael A Newton.;Richard B Halberg.;William M Grady.;Cesare Hassan.;Perry J Pickhardt.
来源: Gut. 2023年72卷12期2321-2328页
The natural history of small polyps is not well established and rests on limited evidence from barium enema studies decades ago. Patients with one or two small polyps (6-9 mm) at screening CT colonography (CTC) are offered CTC surveillance at 3 years but may elect immediate colonoscopy. This practice allows direct observation of the growth of subcentimetre polyps, with histopathological correlation in patients undergoing subsequent polypectomy.

551. Accuracy of measuring colorectal polyp size in pathology: a prospective study.

作者: Roupen Djinbachian.;Abdelhakim Khellaf.;Brandon Noyon.;Geneviève Soucy.;Bich N Nguyen.;Daniel von Renteln.
来源: Gut. 2023年72卷11期2015-2018页

552. B and T cell responses to the BNT162b2 COVID-19 mRNA vaccine are not impaired in germ-free or antibiotic-treated mice.

作者: Todd Norton.;Miriam Anne Lynn.;Charné Rossouw.;Arunasingam Abayasingam.;Griffith Perkins.;Pravin Hissaria.;Rowena Anne Bull.;David John Lynn.
来源: Gut. 2024年73卷7期1222-1224页

553. Fatal intestinal disease: a case of recurrent lower gastrointestinal bleeding.

作者: Cong Dai.;Yu-Hong Huang.
来源: Gut. 2024年73卷4期572-628页

554. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.

作者: Elina En Li Cho.;Chong Zhe Ang.;Jingxuan Quek.;Clarissa Elysia Fu.;Lincoln Kai En Lim.;Zane En Qi Heng.;Darren Jun Hao Tan.;Wen Hui Lim.;Jie Ning Yong.;Rebecca Zeng.;Douglas Chee.;Benjamin Nah.;Cosmas Rinaldi Adithya Lesmana.;Aung Hlaing Bwa.;Khin Maung Win.;Claire Faulkner.;Majd B Aboona.;Mei Chin Lim.;Nicholas Syn.;Anand V Kulkarni.;Hiroyuki Suzuki.;Hirokazu Takahashi.;Nobuharu Tamaki.;Karn Wijarnpreecha.;Daniel Q Huang.;Mark Muthiah.;Cheng Han Ng.;Rohit Loomba.
来源: Gut. 2023年72卷11期2138-2148页
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and chronic inflammation are key pathways in the pathogenesis of T2DM leading to NAFLD and vice versa, with the synergistic effect of NAFLD and T2DM increasing morbidity and mortality risks. This meta-analysis aims to quantify the prevalence of NAFLD and the prevalence of clinically significant and advanced fibrosis in people with T2DM.

555. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+ T cells.

作者: Xing Kang.;Changan Liu.;Yanqiang Ding.;Yunbi Ni.;Fenfen Ji.;Harry Cheuk Hay Lau.;Lanping Jiang.;Joseph Jy Sung.;Sunny H Wong.;Jun Yu.
来源: Gut. 2023年72卷11期2112-2122页
Roseburia intestinalis is a probiotic species that can suppress intestinal inflammation by producing metabolites. We aimed to study the role of R. intestinalis in colorectal tumourigenesis and immunotherapy.

556. Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis.

作者: Pierfrancesco Visaggi.;Brigida Barberio.;Giulio Del Corso.;Nicola de Bortoli.;Christopher J Black.;Alexander C Ford.;Edoardo Savarino.
来源: Gut. 2023年72卷11期2019-2030页
There is currently no recommendation regarding preferred drugs for active eosinophilic oesophagitis (EoE) because their relative efficacy is unclear. We conducted an up-to-date network meta-analysis to compare proton pump inhibitors, off-label and EoE-specific topical steroids, and biologics in EoE.

557. Temporal trend of mortality in patients with cirrhosis with primary biliary cholangitis and primary sclerosing cholangitis during the COVID-19 pandemic.

作者: Xinyuan He.;Ning Gao.;Fan Lv.;Fengping Wu.;Yi Liu.;Lamei Li.;Walid S Ayoub.;Yee Hui Yeo.;Fanpu Ji.
来源: Gut. 2024年73卷7期1217-1219页

558. Catecholamines and inflammation in advanced liver disease: more closely intertwined than expected?

作者: Hans Dieter Nischalke.;Christina Nischalke.;Franziska Schmalz.;Christine Möller.;Benjamin Krämer.;Alexandra Funken.;Adrian Goldspink.;Jacob Nattermann.;Christian Strassburg.;Philipp Lutz.
来源: Gut. 2024年73卷7期1219-1222页

559. Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on Helicobacter pylori Management (Hp-EuReg).

作者: Ángeles Pérez-Aisa.;Olga P Nyssen.;Alma Keco-Huerga.;Luís Rodrigo.;Alfredo J Lucendo.;Blas J Gomez-Rodriguez.;Juan Ortuño.;Mónica Perona.;José María Huguet.;Oscar Núñez.;Luis Fernandez-Salazar.;Jesus Barrio.;Angel Lanas.;Eduardo Iyo.;Pilar Mata Romero.;Miguel Fernández-Bermejo.;Barbara Gomez.;Ana Garre.;Judith Gomez-Camarero.;Luis Javier Lamuela.;Ana Campillo.;Luisa de la Peña-Negro.;Manuel Dominguez Cajal.;Luis Bujanda.;Diego Burgos-Santamaría.;Fernando Bermejo.;Víctor González-Carrera.;Ramón Pajares.;Pedro Almela Notari.;Javier Tejedor-Tejada.;Montserrat Planella.;Itxaso Jiménez.;Yolanda Arguedas Lázaro.;Antonio Cuadrado-Lavín.;Isabel Pérez-Martínez.;Edurne Amorena.;Jesús M Gonzalez-Santiago.;Teresa Angueira.;Virginia Flores.;Samuel J Martínez-Domínguez.;Manuel Pabón-Carrasco.;Benito Velayos.;Alicia Algaba.;Consuelo Ramírez.;Enrique Alfaro Almajano.;Manuel Castro-Fernandez.;Noelia Alcaide.;Patricia Sanz Segura.;Anna Cano-Català.;Natalia García-Morales.;Leticia Moreira.;Francis Mégraud.;Colm O'Morain.;Xavier Calvet.;Javier P Gisbert.
来源: Gut. 2023年72卷11期2031-2038页
The recommended schedule for single capsule bismuth quadruple therapy (scBQT, Pylera) includes a proton pump inhibitor (PPI) two times a day and three scBQT capsules four times a day. Four times a day treatments are inconvenient and reduce adherence. In contrast, adherence improves with three times a day schedules. In clinical practice, many gastroenterologists use four capsule scBQT three times a day. However, the effectiveness and safety of this latter approach remain uncertain.

560. An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles.

作者: Robert S Bresalier.;Carlo Senore.;Graeme P Young.;James Allison.;Robert Benamouzig.;Sally Benton.;Patrick M M Bossuyt.;Luis Caro.;Beatriz Carvalho.;Han-Mo Chiu.;Veerle M H Coupé.;Willemijn de Klaver.;Clasine Maria de Klerk.;Evelien Dekker.;Sunil Dolwani.;Callum G Fraser.;William Grady.;Lydia Guittet.;Samir Gupta.;Stephen P Halloran.;Ulrike Haug.;Geir Hoff.;Steven Itzkowitz.;Tim Kortlever.;Anastasios Koulaouzidis.;Uri Ladabaum.;Beatrice Lauby-Secretan.;Mārcis Leja.;Bernard Levin.;Theodore Robert Levin.;Finlay Macrae.;Gerrit A Meijer.;Joshua Melson.;Colm O'Morain.;Susan Parry.;Linda Rabeneck.;David F Ransohoff.;Roque Sáenz.;Hiroshi Saito.;Silvia Sanduleanu-Dascalescu.;Robert E Schoen.;Kevin Selby.;Harminder Singh.;Robert J C Steele.;Joseph J Y Sung.;Erin Leigh Symonds.;Sidney J Winawer.; .
来源: Gut. 2023年72卷10期1904-1918页
New screening tests for colorectal cancer (CRC) are rapidly emerging. Conducting trials with mortality reduction as the end point supporting their adoption is challenging. We re-examined the principles underlying evaluation of new non-invasive tests in view of technological developments and identification of new biomarkers.
共有 3431 条符合本次的查询结果, 用时 2.5768971 秒